Associations Between Neurobehavioral Symptoms During Breast Cancer Chemotherapy and Patient-Reported Cognitive Impairment 3 or More Years After Chemotherapy
Menée à partir de données portant sur 104 patientes atteintes d'un cancer du sein de stade précoce, cette étude évalue l'association entre des troubles neuro-comportementaux pendant la chimiothérapie et des déficiences cognitives auto-déclarées 3 ans ou plus après les traitements
Background: Many patients with breast cancer report cognitive impairment for several years after treatment. The objective of this study was to describe associations between neurobehavioral symptoms experienced during chemotherapy for early-stage breast cancer and patient-reported cancer-related cognitive impairment (CRCI) ≥ 3 years post-chemotherapy.
Methods: This study is a secondary analysis of women with stage I-III breast cancer who had enrolled in clinical trials promoting self-directed walking during chemotherapy and were re-consented for a study focused on quality-of-life outcomes ≥ 3 years post-chemotherapy. Patient-reported CRCI was assessed using the FACT-Cog PCI (cut point for impairment < 54). Multivariable log-binomial regression models, adjusting for age, race, and education, examined associations between long-term CRCI and baseline demographic characteristics, cancer diagnosis and treatment, and patient-reported neurobehavioral symptoms during chemotherapy and at long-term follow-up.
Results: Among 104 participants, 39% reported CRCI at long-term follow-up, on average 6 years post-chemotherapy [range: 2.9–8.8]. CRCI was more common among those reporting moderate or worse depressive (RR 1.75, 95% CI 1.11–2.75, p = 0.02), anxiety (RR 1.95, 95% CI 1.22–3.11, p = 0.005), or fatigue (RR 1.92, 95% CI 1.09–3.36, p = 0.02) symptoms during chemotherapy. In sensitivity analyses limited to patients with none or mild symptoms prior to chemotherapy, depressive (RR 2.11, 95% CI 1.23–3.63, p = 0.007) and fatigue (RR 1.81, 95% CI 1.81, 95% CI 1.01–3.24, p = 0.05) symptoms emerging during chemotherapy were also associated with CRCI at follow-up.
Conclusions: Patient-reported neurobehavioral symptoms experienced during chemotherapy, including depression, anxiety, and fatigue, were associated with patient-reported CRCI years after primary treatment and should be monitored for timely intervention opportunities.
Psycho-Oncology , résumé, 2026